Corporate | 6 November 2007 07:40
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Quarter Results
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 6 November 2007. Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE 0005659700), a globally active specialist for radioactive
applications in industry and medicine, achieved third-quarter sales of 12.8
million EUR despite the sale of its blood radiation systems business, and
thus increased its cumulative sales as of 30 September 2007 by 3.4 million
EUR or 9.5% over the same period of last year. The EBIT rose to 4.2 million
EUR in the same period, which corresponds to an increase of 4%. The surplus
decreased by 0.8 million EUR to 1.3 million EUR due to special effects from
the corporate tax reform. Without this non-monetary special burden arising
from re-evaluation of losses carried forward, the result would be 0.68 EUR
per share, which is slightly above the level of last year.
Sales in all segments increased over the respective figures for the same
nine-month period of last year. The Radiopharmaceuticals segment once again
showed the strongest growth in sales over last year, with an increase of
48% to 5.4 million EUR. Sales in the Therapy segment grew by 8% to 14.8
million EUR. Sales in the Industry segment showed only a slight nominal
increase of 3% to 19 million EUR. Making allowances the unfavorable
development in the exchange rate between the euro and the US dollar,
however, growth in this segment amounted to 10%.
Regarding the overall profit for 2007, the Board continues to forecast 0.90
EUR per share before special or one-time effects. Taking effects from the
corporate tax reform into account, a result of 0.63 EUR per share is
expected.
For 2008, the Board anticipates further growth in sales and profit. If the
average exchange rate of the US dollar to the euro does not exceed 1.40,
the overall surplus for next year is expected to increase by approximately
10% to 1.00 EUR per share.
Further details on business development in the third quarter are contained
in the Quarterly Report to be released today.
Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin
phone: +49 (0) 30 / 94 10 84-139; fax –112; e-mail: thomas.scheuch@ezag.de,
www.ezag.de
06.11.2007 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------